This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Epizyme Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

15.8%

Kazanç büyüme oranı

16.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	35.0%
Gelir büyüme oranı	37.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:EPE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2024	136	-173	N/A	N/A	3
12/31/2023	80	-196	N/A	N/A	4
12/31/2022	49	-182	N/A	N/A	4
6/30/2022	53	-208	-209	-209	N/A
3/31/2022	38	-236	-211	-210	N/A
12/31/2021	37	-251	-227	-227	N/A
9/30/2021	34	-267	-229	-228	N/A
6/30/2021	33	-257	-229	-228	N/A
3/31/2021	22	-251	-250	-224	N/A
12/31/2020	16	-232	-257	-206	N/A
9/30/2020	12	-222	-239	-189	N/A
6/30/2020	14	-202	-235	-184	N/A
3/31/2020	17	-192	-200	-174	N/A
12/31/2019	24	-173	-148	-147	N/A
9/30/2019	29	-140	-135	-134	N/A
6/30/2019	23	-141	-132	-132	N/A
3/31/2019	30	-122	-123	-123	N/A
12/31/2018	22	-124	-122	-122	N/A
9/30/2018	12	-137	-130	-129	N/A
6/30/2018	12	-137	-133	-133	N/A
3/31/2018	10	-136	-119	-118	N/A
12/31/2017	10	-134	-121	-120	N/A
9/30/2017	10	-133	-112	-111	N/A
6/30/2017	17	-120	-98	-97	N/A
3/31/2017	8	-120	-105	-104	N/A
12/31/2016	8	-110	-97	-96	N/A
9/30/2016	8	-97	-97	-97	N/A
6/30/2016	2	-96	-80	-79	N/A
3/31/2016	2	-94	N/A	-76	N/A
12/31/2015	3	-132	N/A	-73	N/A
9/30/2015	12	-125	N/A	-72	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EPE is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: EPE is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: EPE is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: EPE's revenue (37.6% per year) is forecast to grow faster than the German market (4.7% per year).

Yüksek Büyüme Geliri: EPE's revenue (37.6% per year) is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if EPE's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Epizyme Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.63 loss in 2Q 2021)

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings released: US$0.39 loss per share (vs US$0.69 loss in 1Q 2021)

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Director Kevin Conroy has joined 4th company board

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought €424k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Revenue beats expectations

New 90-day low: €8.50

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: €9.30

Independent Director recently bought €51k worth of stock

New 90-day low: €9.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue misses expectations

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue misses expectations

Epizyme, Inc. Announces Executive Promotions

Epizyme Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

New 90-day low: €10.00

First half earnings released

New 90-day low - €11.60

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin